Advertising and promotion of medicines and medical products
GRATA International’s specialists of the Pharmaceuticals & Healthcare sector released the product on “Advertising and promotion of medicines and medical products” in the following countries: Belarus, Georgia, Kazakhstan, Moldova, Mongolia, and Uzbekistan.
Manufacturing, import, export, storage, sale, monitoring, distribution and use of medicine for human and veterinary use, including conventional medicine, bio preparations, diagnostics (hereinafter the “Medicine”), medical devices, and biologically active products are regulated by the Law of Mongolia on Medicines and Medical Devices. The Law also provides a few broad limitations on the advertising of medicines and biologically active products. In addition to this regulation, the Law of Mongolia on Advertisement governs advertising in health sector.
The covid-19 pandemic highlighted the need to develop healthcare in Kazakhstan, in particular by increasing the number of healthcare facilities, modernising the existing ones and providing them with modern equipment, and by improving skills of healthcare personnel.
Until December 2020, the Ministry of Health, the Centre for Health Development and the relevant departments of the General Agency of Specialized Inspection were responsible for the regulation with regards to import, export and distribution of medicines and medical devices under their respective functions.
This is to inform you that on 19 December 2020, the Law of the Republic of Kazakhstan ‘On the Introduction of the Amendments to Some Legislative Acts of the Republic of Kazakhstan on outstaffing services’ (hereinafter – the ‘Law’). Pursuant to the Law, the Labour Code of the Republic of Kazakhstan
This article covers such sensitive topic as tax exemption of dividends distributed by a Kazakh company in address of its foreign shareholders (participants). In particular, the recent tendency in the approach of the Kazakh tax authorities adopted in this regard.
Naphtyzinum: ‘Soviet’ Trademark or Public Interest?
In Kazakhstan’s judicial practice there are growing disputes related to the early termination of legal protection for trademarks that have come into common use for the designation of goods of a certain type by virtue of Article 6.1.1 of the Law of the Republic of Kazakhstan 'On Trademarks, Service Marks and Appellations of Origin of Goods' No. 456-I, dated 26 June 1999 (hereinafter - the 'Trademark Law').
As outlined in our earlier Overview of main developments in pharmaceuticals regulations of Kazakhstan in 2019, as a result of steady dynamic of medicines prices, we observe the same dynamic in continuous changes of legislative framework governing the pricing of medicines.
Aidar Oruzbaev, lawyer of Bishkek office of Grata International leading pharmaceutical law practice in the Kyrgyz Republic breaks down the main features of newly adopted Decree of the Kyrgyz Government on measures concerning prevention of further spread of COVID-19.
The new rules for regulating the prices of medicines ('Price Regulation Rules 2019') were adopted in April 2019. Over the past five years, this is the third regulatory legal act establishing the procedure for regulating the prices of medicines.
Currently, the pharmaceutical industry in Uzbekistan is experiencing a modification of regulatory requirements. In recent years, the country has achieved positive results in the formation and development of the primary health care system for population.
Guidelines for the selection of trade names of medicines and for manufacturing of finished dosage forms in the Eurasian Economic Union
The Board of the Eurasian Economic Commission (EEC) approved on 29 January 2019 the Recommendations on the Guidelines for the Selection of Trade Names of Medicinal Products and the Guidelines for Manufacturing of Finished Dosage Forms of Medicinal Products in order to eliminate differences in the requirements for the manufacturing of finished dosage forms of medicines in Eurasian Member States Economic Union (EAEU).